ArticleData in brief2025
Data set of m6A methylation-related RNAs from patients of papillary thyroid carcinoma without autoimmune thyroid disease.
Article in Data in brief, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This dataset focuses on N6-Methyladenosine (m6A) RNA methylation in papillary thyroid carcinoma (PTC) without autoimmune thyroid disease (AITD). Emerging evidence suggests that m6A modification was associated with the occurrence and progression of both thyroid carcinoma and AITD. Given the substantial clinical overlap between thyroid carcinoma (particularly PTC) and AITD, rigorous exclusion of autoimmune confounding factors is essential to isolate the distinct role of m6A modifications in driving thyroid carcinogenesis and progression. Here, mRNA & lncRNA Epitranscriptomic Microarray technology was applied to investigate on the role of m6A-modification using thyroid tissue pairs of cancerous and para-cancerous from three patients of PTC without AITD enrolled from the First Affiliated Hospital, Fujian Medical University, Fuzhou, China. The data analysis involved normalization, quantification, and identification of differentially m6A-modified transcripts and mRNA expression. Subsequently, clustering and functional enrichment analyses (including Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG)) were conducted to gain an initial understanding of the biological significance of m6A modifications in PTC without AITD. This data set provides the m6A methylation profiles of PTC without AITD and allowed for the further study in this specific pathological context.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.